A Multicenter, Phase 1/2, Open-Label Study Evaluating the Tolerability, Safety, Pharmacokinetics, and Efficacy of AMG 337 in Asian Subjects
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs AMG 337 (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Amgen
- 11 Aug 2017 Planned End Date changed from 28 Sep 2017 to 29 Dec 2017.
- 22 Jun 2017 Planned End Date changed from 1 Jun 2017 to 28 Sep 2017.
- 10 Jun 2017 Biomarkers information updated